NR4A1 and breast cancer: Third, since it was not possible to include only patients, who had postmenopausal hormone receptor-positive, HER2-negative advanced breast cancer treatments after failure of treatment with letrozole or anastrozole, patients in this study could be at any stage of breast cancer.